Q BioMed Inc.
QBIO · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -80.1% | -52.3% | -84.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 0% | -539.8% | -152.9% | 57.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -17,800.4% | 20,597.2% | -2,973.2% | -548.1% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -33,056.4% | 18,368.3% | -3,081.3% | -1,110% |
| EPS | -0.008 | 0.051 | -0.018 | -0.057 |
| % Growth | -114.8% | 385.6% | 68.6% | – |
| EPS Diluted | -0.008 | 0.051 | -0.018 | -0.057 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -17,300.4% | -4,412.4% | -2,066.8% | -471.6% |